How government health insurance coverage of novel anti-cancer medicines benefited patients in China - a retrospective analysis of hospital clinical data

• Hoofdauteurs: Yifan Diao (Auteur), Mengbo Lin (Auteur), Kai Xu (Auteur), Ji Huang (Auteur), Xiongwei Wu (Auteur), Mingshuang Li (Auteur), Jing Sun (Auteur), Hong Li (Auteur)
• Formaat: Boek
• Gepubliceerd in: BMC, 2021-08-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Abstract Background China started to cover novel medicines for the treatment of major cancers, such as trastuzumab for breast cancer by the government health insurance programs since 2016. Limited data have been published on the use of cancer medications and little is known about how government heal...